India, with over 101 million diabetes patients and rising obesity rates, faces a critical need for effective treatment ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro tripeptide Read ahead ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Further, it is also an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...